Q4 2024 CV Sciences Inc Earnings Call Transcript
Key Points
- CV Sciences Inc (CVSI) achieved a gross margin improvement from 44.3% in 2023 to 45.6% in 2024, indicating better cost management.
- The company successfully launched the +PlusHLTH line of cannabinoid-free supplements, which has been well-received by consumers and retailers.
- CV Sciences Inc (CVSI) expanded its product line with new CBD pet products and entered a strategic relationship with Chewy, enhancing its distribution channels.
- The acquisition of cultured foods and elevated softgels is expected to bring increased scale, distribution, and cost efficiency to the company.
- CV Sciences Inc (CVSI) maintained its revenue at $15.7 million in a challenging market, showing resilience compared to competitors experiencing declines.
- Year-over-year revenue slightly decreased from $16 million in 2023 to $15.7 million in 2024, reflecting challenges in the market.
- The company reported an operating loss of $0.6 million for the fourth quarter of 2024, indicating ongoing financial challenges.
- CV Sciences Inc (CVSI) ended the fourth quarter of 2024 with a reduced cash position of $0.5 million compared to $1.3 million at the end of 2023.
- The regulatory environment remains challenging, with the absence of federal regulation leading to costly compliance issues.
- Despite cost reductions, the company continues to face a fragmented and competitive CBD market, which may impact future growth.
Greetings and welcome to the CV Sciences fourth quarter and year end, 2024 financial results conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Brendan Hawkins. Thank you, sir. You may begin.
Thank you and good morning, everyone. With us today with prepared remarks are CV Sciences' Chief Executive Officer, Joseph Dowling, and Joerg Grasser, Chief Financial Officer. After prepared remarks, we will take questions from the analyst community.
I'd like to remind everyone that during this call, management's prepared remarks may contain forward-looking statements. These forward-looking statements are subject to risk and uncertainties that may cause actual results to differ materially from those anticipated by CV Sciences at this time.
When used in this call, the words
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
